

Medication Template

STUDENT NAME: Lauren Jenks

MEDICATION: Milrinone (Primacor)

PHARMACOLOGIC CLASSIFICATION:
Phosphodiesterase Inhibitor

THERAPEUTIC CLASSIFICATION:
Inotropics

PHARMACOLOGICAL ACTIONS

- Increases myocardial contractility
- Decreases preload and afterload by a direct dilating effect on vascular smooth muscle

THERAPEUTIC EFFECTS

Increased cardiac output (inotropic effect)

ADVERSE REACTIONS/SIDE EFFECTS

- Ventricular arrhythmias
- Skin rash
- Angina pectoris
- Headache/tremor
- Hypotension
- Supraventricular arrhythmias
- Increased liver enzymes
- Hypokalemia
- thrombocytopenia

MEDICATION INTERACTIONS

- Nonsignificant

CONTRAINDICATIONS/PRECAUTIONS

Contraindication: hypersensitivity

Contraindication: Severe aortic or pulmonic valvular heart disease

Contraindication: hypertrophic subaortic stenosis

Precaution: history of arrhythmias, electrolyte abnormalities, abnormal digoxin levels, or insertion of vascular catheters

Precaution: renal impairment

Precaution: Pregnancy or lactation

NURSING INTERVENTIONS

- Monitor HR and BP continuously during administration
- Monitor intake and output and daily weight
- Monitor EKG continuously during infusion
- Monitor platelet count during therapy
- Monitor electrolytes and renal function – correct hypokalemia before administration
- Monitor toxicity – hypotension

ROUTES/ADULT DOSAGES

- IV (adults) loading dose: 50 mcg/kg
- IV (adults) continuous infusion: 0.5 mcg/kg/min
- IV (infants and children) loading dose: 50 mcg/kg over 10 min
- IV (infants and children) continuous infusion: 0.5 mcg/kg/min

CLIENT EDUCATION

- Inform pt and family of reasons for administration – not a cure but is a temporary measure to control symptoms of HF